1. Did the subject meet all the entry criteria?

1. Signed written informed consent prior to beginning study-related procedures.

2. Male or female aged at least 18 years, inclusive, at screening. Female subjects must be post-menopausal or using a highly effective method for avoidance of pregnancy.

3. Current treatment with statin therapy unless not indicated according to treatment guidelines or contraindicated in the opinion of the investigator.

4. Chronic CHD documented

At least one additional predictor of CV risk

1. Planned coronary revascularization (PCI or CABG) or any other major surgical procedure.

2. Current liver disease, known hepatic or biliary abnormalities or evidence of abnormal liver function test or other hepatic abnormalities.

3. Severe renal impairment (eGFR <30 mL/min/1.73 m2) or history of nephrectomy or kidney transplant (regardless of renal function).

4. Current severe heart failure (New York Heart Association class III or IV).

5. Poorly controlled hypertension despite lifestyle modifications and pharmacotherapy.

6. Any life-threatening condition with life expectancy <2 years, other than vascular disease, that might prevent the subject from completing the study.

7. Severe asthma that is poorly controlled on pharmacotherapy.

8. Positive pregnancy test or is known to be pregnant or lactating.

9. History of anaphylaxis, anaphylactoid (resembling anaphylaxis) reactions, or severe allergic responses.

10. Alcohol or drug abuse within the past 6 months, or current mental condition (psychiatric disorder, senility or dementia), which may affect study compliance or prevent understanding of the aims, investigational procedures or possible consequences of the study.

11. Current or planned chronic administration of strong oral or injectable cytochrome P-450 isoenzyme 3A4 (CYP3A4) inhibitors.

12. Subjects with both parents of Japanese, Chinese or Korean ancestry must have a blood sample collected for assessment of Lp-PLA2 activity by the central laboratory prior to randomization. Those with Lp-PLA 2 activity <10 nmol/min/mL will be excluded from participation in the study.

13. Previous exposure to darapladib (SB-480848).

14. Use of another investigational product within 30 days or 5 half-lives (whichever is the longer) preceding the first dose of darapladib or matching placebo.

15. Currently in a study of an investigational device.

16. Any other reason the investigator deems the subject to be unsuitable for the study.